Other headlinesIntelerad customer base surges
GE adds intracardiac echo catheters
The Vividi and Vividq ultrasound systems from GE Healthcare now can be equipped with intracardiac echo (ICE) catheters from Biosense Webster. Vividi systems with version BT10 software support the Biosense Webster AcuNav 8F ICE catheter, featuring a 33% smaller cross sectional area than the AcuNav 10F catheter. Vividi and Vividq systems are also compatible with the SoundStar 3D ICE catheters, as well as with the Biosense Webster CartoXP system with the CartoSound version 9.7 software module. CartoSound and the SoundStar 3D catheters integrate real-time intracardiac echocardiography imaging, enhancing visualization and navigational confidence during complex EP procedures.
Intelerad customer base surges
Orders and installations in the U.S., Australia, and Canada have expanded the customer base of PACS/IT vendor Intelerad Medical Systems. More than a dozen sites have recently signed up for PACS and workflow management products from Intelerad, according to the company. Among them are St. Vincent General Hospital District of Leadville, CO; Ultrasound Care of Sydney; and Breast Centre Radiology in Edmonton.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.